Search research articles
Contact Us
Filters
Showing results (291-300 of 297) with videos related to
Page
of 30
Sort By:
You have reached the last page of results.
This site can display upto 297 results.
The Lancet. Global Health
|
August 9, 2014
Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial
Thomas J Coates, Michal Kulich, David D Celentano, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Revue Des Maladies Respiratoires
|
May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]
V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†
J-L Pujol, A Lavole, E Quoix, et al.
Plos One
|
July 23, 2013
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043)
Oliver Laeyendecker, Estelle Piwowar-Manning, Agnes Fiamma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
M Beau-Faller, N Prim, A-M Ruppert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
G Zalcman, A Madroszyk, E Guenzi, et al.
Page
of 30
Search research articles
Search
Showing results (291-300 of 297) with videos related to
Sort By:
Page
of 30
You have reached the last page of results.
This site can display upto 297 results.
The Lancet. Global Health
|
August 9, 2014
Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial
Thomas J Coates, Michal Kulich, David D Celentano, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
H Blons, J-B Oudart, J-P Merlio, et al.
Revue Des Maladies Respiratoires
|
May 24, 2007
[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]
V Westeel, M P Lebitasy, M Mercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†
J-L Pujol, A Lavole, E Quoix, et al.
Plos One
|
July 23, 2013
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043)
Oliver Laeyendecker, Estelle Piwowar-Manning, Agnes Fiamma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
M Beau-Faller, N Prim, A-M Ruppert, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 14, 2026
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
G Zalcman, A Madroszyk, E Guenzi, et al.
Page
of 30